| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8446093 | European Journal of Cancer | 2012 | 7 Pages |
Abstract
FcγR polymorphisms may play a role in the clinical efficacy of Cetuximab in EGFR downstream mutated mCRC patients. Further research into Cetuximab immune-based mechanisms in KRAS-mutated patients seems warranted.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Javier RodrÃguez, Ruth Zarate, Eva Bandres, Valentina Boni, Amaia Hernández, Jesus Javier Sola, Beatriz Honorato, Nerea Bitarte, Jesus GarcÃa-Foncillas,